This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tyndall, A Search for Related Content PubMed PubMed Citation Articles by Tyndall, A Social Bookmarking                         What's this?

Cellular therapy of systemic lupus erythematosus

Department of Rheumatology, University of Basel, Felix Platter Hospital, Burgfelderstrasse 101, 4012, Basel, Switzerland alan.tyndall{at}fps-basel.ch

Immunoablation with autologous hematopoietic stem cell rescue has been used in over 1,300 autoimmune disease patients, around 150 with SLE. Some patients have experienced durable remissions with loss of autoantibodies, whereas others either did not respond or died as a result of the treatment. Prospective randomised trials are required and are being planned to establish the place for this potentailly curative strategy. Mesenchymal stem cells are in an exploratory phase for the treatment of acute autoimmune disease including SLE. The principle is that they home to inflammed tissue and exert an antiinflammatory paracrine effect.

Key Words: autoimmune disease • lupus • MSC • stem cell • transplantation

Lupus, Vol. 18, No. 5, 387-393 (2009)
DOI: 10.1177/0961203308100385


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Bouffi, F. Djouad, M. Mathieu, D. Noel, and C. Jorgensen Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology, October 1, 2009; 48(10): 1185 - 1189. [Abstract] [Full Text] [PDF]